Edition:
United Kingdom

Resmed Inc (RMD.N)

RMD.N on New York Stock Exchange

100.35USD
23 Jan 2018
Change (% chg)

$12.84 (+14.67%)
Prev Close
$87.51
Open
$98.96
Day's High
$104.78
Day's Low
$97.45
Volume
885,204
Avg. Vol
194,150
52-wk High
$104.78
52-wk Low
$62.76

Chart for

About

ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD),... (more)

Overall

Beta: 0.77
Market Cap(Mil.): $10,992.71
Shares Outstanding(Mil.): 142.30
Dividend: 0.35
Yield (%): 1.81

Financials

  Industry Sector
P/E (TTM): -- 149.38 16.62
EPS (TTM): -- -- --
ROI: -- 9.44 10.61
ROE: -- 14.87 14.21

BRIEF-ResMed Q2 Gaap Earnings Per Share $0.07

* ANNOUNCES RESULTS FOR THE SECOND QUARTER OF FISCAL YEAR 2018

22 Jan 2018

NZ's Fisher & Paykel sues Resmed in Australia over patent dispute

New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents.

12 Dec 2017

UPDATE 1-NZ's Fisher & Paykel sues Resmed in Australia over patent dispute

Dec 12 New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents.

12 Dec 2017

NZ's Fisher & Paykel sues Resmed in patent dispute

Dec 12 New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents.

12 Dec 2017

BRIEF-Resmed Inc elects Karen Drexler to its board of directors

* Resmed elects Karen Drexler to its board of directors Source text for Eikon: Further company coverage:

17 Nov 2017

BRIEF-Resmed updates on United Kingdom case with Fisher & Paykel​

* Ruling has no impact on Resmed's commercial operations in UK​

13 Nov 2017

Fisher & Paykel says UK court rules rival Resmed's patent is invalid

WELLINGTON New Zealand's Fisher & Paykel Healthcare said on Monday that it could continue to sell its sleep apnea masks in Britain as a UK court had ruled that rival Resmed Inc's patent was invalid.

12 Nov 2017

UPDATE 1-Fisher & Paykel says UK court rules rival Resmed's patent is invalid

* UK court rules Resmed's patent for mask invalid - F&P Healthcare

12 Nov 2017

Fisher & Paykel says UK court rules rival Resmed's patent is invalid

WELLINGTON, Nov 13 A British court has ruled that a patent held by health appliance firm Resmed Inc for a mask that treats sleep apnea was invalid, rival firm Fisher & Paykel Healthcare said on Monday.

12 Nov 2017

Earnings vs. Estimates